Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

LP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variant

Texto completo
Autor(es):
Mostrar menos -
Prates-Syed, Wasim A. [1, 2] ; Chaves, Lorena C. S. [3] ; Crema, Karin P. [1, 2] ; Vuitika, Larissa [1] ; Lira, Aline [1, 2] ; Cortes, Nelson [1, 2] ; Kersten, Victor [1] ; Guimaraes, Francisco E. G. [4] ; Sadraeian, Mohammad [4, 5] ; Barroso da Silva, Fernando L. [6, 7] ; Cabral-Marques, Otavio [8, 1, 9] ; Barbuto, Jose A. M. [1, 10] ; Russo, Momtchilo [1] ; Camara, Niels O. S. [1] ; Cabral-Miranda, Gustavo [1, 2]
Número total de Autores: 15
Afiliação do(s) autor(es):
[1] Univ Sao Paulo ICB USP, Inst Biomed Sci, Dept Immunol, BR-05508000 Sao Paulo, SP - Brazil
[2] Inst Res & Educ Child Hlth PENSI, BR-01228200 Sao Paulo, SP - Brazil
[3] Emory Univ, Sch Med, Dept Microbiol & Immunol, Claudia Nance Rollins Bldg, Atlanta, GA 30329 - USA
[4] IFSC USP, Sao Carlos Inst Phys, BR-13566590 Sao Carlos, SP - Brazil
[5] Univ Technol, Inst Biomed Mat & Devices IBMD, Fac Sci, Sydney, NSW 2007 - Australia
[6] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Biomol Sci, BR-14040903 Ribeirao Preto, SP - Brazil
[7] North Carolina State Univ, Dept Chem & Biomol Engeneering, Raleigh, NC 27695 - USA
[8] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, BR-05508000 Sao Paulo, SP - Brazil
[9] Univ Sci Educ & Res Network USERN, Childrens Med Ctr, Network Immun Infect, Malignancy & Autoimmun NIIMA, Tehran 1419733151 - Iran
[10] Univ Sao Paulo, Hosp Clin HCFMUSP, Dept Hematol, Lab Med Invest Pathogenesis & Targeted Therap Onc, BR-0124690 Sao Paulo, SP - Brazil
Número total de Afiliações: 10
Tipo de documento: Artigo Científico
Fonte: VACCINES; v. 9, n. 12 DEC 2021.
Citações Web of Science: 0
Resumo

Virus-like particles (VLPs) are a versatile, safe, and highly immunogenic vaccine platform. Recently, there are developmental vaccines targeting SARS-CoV-2, the causative agent of COVID-19. The COVID-19 pandemic affected humanity worldwide, bringing out incomputable human and financial losses. The race for better, more efficacious vaccines is happening almost simultaneously as the virus increasingly produces variants of concern (VOCs). The VOCs Alpha, Beta, Gamma, and Delta share common mutations mainly in the spike receptor-binding domain (RBD), demonstrating convergent evolution, associated with increased transmissibility and immune evasion. Thus, the identification and understanding of these mutations is crucial for the production of new, optimized vaccines. The use of a very flexible vaccine platform in COVID-19 vaccine development is an important feature that cannot be ignored. Incorporating the spike protein and its variations into VLP vaccines is a desirable strategy as the morphology and size of VLPs allows for better presentation of several different antigens. Furthermore, VLPs elicit robust humoral and cellular immune responses, which are safe, and have been studied not only against SARS-CoV-2 but against other coronaviruses as well. Here, we describe the recent advances and improvements in vaccine development using VLP technology. (AU)

Processo FAPESP: 20/05146-7 - Desenvolvimento de vacina anti-SARS-CoV-2 utilizando VLPs
Beneficiário:Gustavo Cabral de Miranda
Modalidade de apoio: Auxílio à Pesquisa - Regular
Processo FAPESP: 20/07158-2 - Desenvolvendo e aplicando métodos de simulação computacional para melhorar a compreensão molecular para a engenharia de biomateriais funcionalizados
Beneficiário:Fernando Luis Barroso da Silva
Modalidade de apoio: Auxílio à Pesquisa - Regular
Processo FAPESP: 17/10910-5 - Produção e caracterização de novos fotoimunoconjugados para fotoimunoterapia do HIV
Beneficiário:Mohammad Sadraeian
Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 19/14526-0 - Desenvolvimento de vacinas contra Streptococcus pyogenes e Chikungunya utilizando VLPs
Beneficiário:Gustavo Cabral de Miranda
Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores